Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,086,140 papers from all fields of science
Search
Sign In
Create Free Account
Myeloablative Chemotherapy
High-dose chemotherapy that kills cells in the bone marrow, including cancer cells. It lowers the number of normal blood-forming cells in the bone…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major
A. Hussein
,
A. Al‐Zaben
,
+7 authors
H. Frangoul
Pediatric Blood & Cancer
2013
Corpus ID: 38391518
Patients with thalassemia in developing countries have limited access to safe transfusions, regular medical care and chelation…
Expand
Review
2013
Review
2013
Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia.
R. Champlin
Baillière's Best Practice & Research: Clinical…
2013
Corpus ID: 46303572
2009
2009
Management and outcome of stage 3 neuroblastoma.
S. Modak
,
B. Kushner
,
M. LaQuaglia
,
K. Kramer
,
N. Cheung
European Journal of Cancer
2009
Corpus ID: 31830940
Review
2009
Review
2009
Reduced-intensity conditioning and umbilical cord blood transplantation in adults
C. Cutler
,
K. Ballen
Bone Marrow Transplantation
2009
Corpus ID: 20130881
Reduced-intensity conditioning (RIC) preparative regimens are now widely used in umbilical cord blood (UCB) transplantation…
Expand
Review
2008
Review
2008
Reduced intensity and non‐myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non‐malignant diseases
P. Satwani
,
E. Morris
,
M. Bradley
,
M. Bhatia
,
C. van de Ven
,
M. Cairo
Pediatric Blood & Cancer
2008
Corpus ID: 34822465
Allogeneic hematopoietic stem cell transplant (AlloSCT) from related or unrelated histocompatible donors has been well…
Expand
2008
2008
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: Outcome compared with conventional chemotherapy: A report from the…
J. Finlay
,
G. Dhall
,
+10 authors
R. Packer
Pediatric Blood & Cancer
2008
Corpus ID: 28278899
Children and adolescents with malignant astrocytomas recurring after initial treatment have a dismal prognosis, with only rare…
Expand
Highly Cited
2002
Highly Cited
2002
Treatment of high‐risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co‐infusion of T cell‐depleted haematopoietic stem cells and culture‐expanded marrow mesenchymal stem…
Seung Tae Lee
,
J. Jang
,
+5 authors
Y. Min
British Journal of Haematology
2002
Corpus ID: 1043596
Summary. A 20‐year‐old woman with high‐risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating…
Expand
Highly Cited
2002
Highly Cited
2002
Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem…
민유홍
,
정준원
2002
Corpus ID: 115230142
2002
2002
Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies
M. Bartlett
,
M. Webb
,
S. Durrant
,
J. Morton
,
R. Allison
,
D. MacFarlane
European Journal of Nuclear Medicine and…
2002
Corpus ID: 22768612
Abstract. Standard treatment regimens for haematological malignancies include myeloablative chemoradiotherapy and subsequent…
Expand
Review
1989
Review
1989
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
T. Ahmed
,
D. Ciavarella
,
+7 authors
Z. Arlin
Leukemia
1989
Corpus ID: 39575281
Twenty three patients with Hodgkin's disease were treated with BCNU (carmustine), etoposide, and cyclophosphamide at doses of 450…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE